News | June 04, 2022
Innate Pharma announces IPH5201 phase 2 study in lung cancer
Innate to receive $5M milestone payment from AstraZeneca
Innate to receive $5M milestone payment from AstraZeneca
Follows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategy
Taiyin Yang, PhD, Executive Vice President, Pharmaceutical Development and Manufacturing to Retire After 29 Years at Gilead
Companies concluded memorandum of understanding that Takeda will continue to provide distribution support for the Moderna COVID-19 vaccines for a transitional period
Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
The new IGX-Track App adds seamless analysis of antibody panning campaigns to the IGX Platform
New block enhances the company's global capabilities in Oral Solid Dosage (OSD) Forms, increasing total plant capacity to 4.5 billion doses
Pfizer calls upon global health leaders and organizations to join the Accord, bringing their expertise and resources to close the health equity gap
The technology was able to identify approximately 32 percent more adenomas than standard colonoscopy procedures
Subscribe To Our Newsletter & Stay Updated
